This site is intended for healthcare professionals

FDA accepts filing of Tyvyt + Alimta for non-small cell lung cancer.- Innovent Biologics and Eli Lilly

Read time: 1 mins
Last updated:28th Jun 2021
Published:19th May 2021
Innovent Biologics and Eli Lilly and Company announced that the FDA accepted for review a Biologics License Application (BLA) for Tyvyt (sintilimab injection) in combination with Alimta (pemetrexed) and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC).
Condition: Non Small Cell Lung Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest